Vertex Pharmaceuticals VRTX
NASDAQ VRTX
$523.93 -11.24 (-2.10%)
At close: Oct 23, 2026 · 4:00 PM EDT

Vertex Pharmaceuticals (VRTX) Gains from Sales and Divestitures (2009 - 2013)

Updated

Vertex Pharmaceuticals' Gains from Sales and Divestitures came in at -$23,000 for Q1 2013.

Analysis

Vertex Pharmaceuticals (VRTX) Gains from Sales and Divestitures (2009 - 2013) Analysis & Trends

Over the trailing twelve months to Mar 31, 2013, Vertex Pharmaceuticals reported Gains from Sales and Divestitures of -$384,000; for FY2012, it was -$390,000.

  • Going back by year, Gains from Sales and Divestitures was -$55,000 in FY2011, -$39,000 in FY2010 and -$2.21 million in FY2009.
  • The Q1 2013 figure represents the highest quarterly Gains from Sales and Divestitures since Q4 2010.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Vertex Pharmaceuticals 132.74 Bn 104.74 Bn 2.84 Bn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2013 -23,000.00
Dec 31, 2012 -344,000.00
Dec 31, 2010 -17,000.00
Mar 31, 2010 -22,000.00
Dec 31, 2009 22,000.00
Sep 30, 2009 -157,000.00
Jun 30, 2009 -20,000.00
Mar 31, 2009 -2.06 Mn
API Access

Vertex Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=VRTX&period=max&api_key=YOUR_API_KEY